Fulcrum Therapeutics (NASDAQ:FULC) has been assigned an average broker rating score of 1.17 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company.

Brokerages have set a 1-year consensus price objective of $22.67 for the company and are predicting that the company will post ($2.08) EPS for the current quarter, according to Zacks. Zacks has also assigned Fulcrum Therapeutics an industry rank of 90 out of 256 based on the ratings given to its competitors.

A number of equities research analysts have recently weighed in on the company. Morgan Stanley assumed coverage on Fulcrum Therapeutics in a research report on Monday, August 12th. They issued an “overweight” rating and a $29.00 price objective on the stock. Bank of America assumed coverage on Fulcrum Therapeutics in a research report on Monday, August 12th. They issued a “buy” rating and a $19.00 price objective on the stock. Finally, Svb Leerink reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Monday, August 12th.

Shares of FULC stock traded down $0.22 during trading hours on Tuesday, reaching $9.04. The company’s stock had a trading volume of 39,300 shares, compared to its average volume of 78,936. Fulcrum Therapeutics has a one year low of $8.19 and a one year high of $15.94.

In other news, Director Mark J. Levin bought 81,250 shares of the stock in a transaction dated Monday, July 22nd. The stock was bought at an average price of $16.00 per share, for a total transaction of $1,300,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder 6 Dimensions Capital, L.P. bought 118,750 shares of the stock in a transaction dated Monday, July 22nd. The stock was purchased at an average price of $16.00 per share, with a total value of $1,900,000.00. The disclosure for this purchase can be found here.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.

Featured Article: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on Fulcrum Therapeutics (FULC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.